Skip to content

Exploring the use of information films to improve patient understanding of genomic expression profiling (GEP) tests in the breast cancer setting

IMproving PAtient undeRstanding of GEP TEst Results: Phase 4

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN28497350
Enrollment
250
Registered
2022-02-11
Start date
2022-02-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Malignant neoplasm of breast

Interventions

This is a randomised trial using quantitative methods. Participants will complete questionnaires and take part in a verbal knowledge assessment with a researcher in relation to GEP testing. Patient o

Sponsors

University of Sussex
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. First presentation of early stage breast cancer with all known disease surgically removed 2. Oestrogen Receptor (ER+ve) and HER-2 negative (female patients only) 3. No clear decision as to whether chemotherapy should be given as adjunct based on current prognostic criteria 4. Consented to GEP tests 5. Able to give full informed consent to IMPARTER:4 6. Good comprehension of the English language 7. Access to internet connection and compatible devices

Exclusion criteria

Exclusion criteria: 1. Other breast cancer diagnosis e.g. DCIS, metastatic 2. Unable to give fully informed consent 3. Under 18 years of age 4. Unable to understand and speak English 5. No access to internet connection and/or compatible devices

Design outcomes

Primary

MeasureTime frame
Patients’ knowledge and understanding about GEP tests and risk of recurrence results measured by a knowledge interview prior to a patient receiving their GEP test results

Secondary

MeasureTime frame
1. The impact of anxiety, intolerance of uncertainty and decisional conflict on decision-making (patient) assessed by the state (baseline and T2) and trait STAI measures (baseline), intolerance of uncertainty (T1) and decisional conflict measure (T2) 2. The confidence/satisfaction with GEP test result consultations (clinician) completed following the test result consultation 3. The agreement between clinician and patient on their treatment decision and whether this is influenced by the clinician’s satisfaction with interview about recurrence risk and IoU scores (clinician completes once per study prior to seeing patients), the patient’s recurrence risk, or pre-existing characteristics (trait anxiety, uncertainty) and whether GEP knowledge/understanding mitigate these

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026